Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ji, Xuening
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
Duan, Wei
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	Completed	3	257	RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases	07/24	07/24
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)	Completed	3	168	RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Type 2 Diabetes	10/24	10/24
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Recruiting	2	196	RoW	TQB2450, Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Endometrial Cancer	12/21	04/22
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian	Completed	2	150	US, RoW	Paclitaxel, Afuresertib, LAE002	Laekna Limited	Platinum-resistant Ovarian Cancer	07/23	06/24
Wang, Ruoyu NA
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer	Recruiting	2	64	RoW	GT101 injection, Gemcitabine injection	Grit Biotechnology	Adult	01/27	01/27